Changes in patients' symptoms and gastric emptying after Helicobacter pylori treatment

World J Gastroenterol. 2016 May 14;22(18):4585-93. doi: 10.3748/wjg.v22.i18.4585.

Abstract

Aim: To investigate the changes in clinical symptoms and gastric emptying and their association in functional dyspepsia (FD) patients.

Methods: Seventy FD patients were enrolled and divided into 2 groups Helicobacter pylori (H. pylori)-negative group (28 patients), and H. pylori-positive group (42 patients). Patients in the H. pylori-positive group were further randomly divided into groups: H. pylori-treatment group (21 patients) and conventional treatment group (21 patients). Seventy two healthy subjects were selected as the control group. The proximal and distal stomach area was measured by ultrasound immediately after patients took the test meal, and at 20, 40, 60 and 90 min; then, gastric half-emptying time was calculated. The incidence of symptoms and gastric half-emptying time between the FD and control groups were compared. The H. pylori-negative and conventional treatment groups were given conventional treatment: domperidone 0.6 mg/(kg/d) for 1 mo. The H. pylori-treatment group was given H. pylori eradication treatment + conventional treatment: lansoprazole 30 mg once daily, clarithromycin 0.5 g twice daily and amoxicillin 1.0 g twice daily for 1 wk, then domperidone 0.6 mg/(kg/d) for 1 mo. The incidence of symptoms and gastric emptying were compared between the FD and control groups. The relationship between dyspeptic symptoms and gastric half-emptying time in the FD and control groups were analyzed. Then total symptom scores before and after treatment and gastric half-emptying time were compared among the 3 groups.

Results: The incidence of abdominal pain, epigastric burning sensation, abdominal distension, nausea, belching, and early satiety symptoms in the FD group were significantly higher than in the control group (50.0% vs 20.8%; 37.1% vs 12.5%; 78.6% vs 44.4%; 45.7% vs 22.2%; 52.9% vs 15.3%; 57.1% vs 19.4%; all P < 0.05). The gastric half-emptying times of the proximal end, distal end, and the whole stomach in the FD group were slower than in the control group (93.7 ± 26.2 vs 72.0 ± 14.3; 102.2 ± 26.4 vs 87.5 ± 18.2; 102.1 ± 28.6 vs 78.3 ± 14.1; all P < 0.05). Abdominal distension, belching and early satiety had an effect on distal gastric half-emptying time (P < 0.05). Abdominal distension and abdominal pain had an effect on the gastric half-emptying time of the whole stomach (P < 0.05). All were risk factors (odds ratio > 1). The total symptom score of the 3 groups after treatment was lower than before treatment (P < 0.05). Total symptom scores after treatment in the H. pylori-treatment group and H. pylori-negative group were lower than in the conventional treatment group (5.15 ± 2.27 vs 7.02 ± 3.04, 4.93 ± 3.22 vs 7.02 ± 3.04, All P < 0.05). The gastric half-emptying times of the proximal end, distal end, and the whole stomach in the H. pylori-negative and H. pylori-treatment groups were shorter than in the conventional treatment group (P < 0.05).

Conclusion: FD patients have delayed gastric emptying. H. pylori infection treatment helps to improve symptoms of dyspepsia and is a reasonable choice for treatment in clinical practice.

Keywords: Functional dyspepsia; Gastric emptying; Ultrasound.

Publication types

  • Observational Study

MeSH terms

  • Abdominal Pain / drug therapy
  • Abdominal Pain / microbiology
  • Abdominal Pain / physiopathology
  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Chi-Square Distribution
  • Dopamine Antagonists / therapeutic use*
  • Dyspepsia / diagnosis
  • Dyspepsia / drug therapy*
  • Dyspepsia / microbiology
  • Dyspepsia / physiopathology
  • Eructation / drug therapy
  • Eructation / microbiology
  • Eructation / physiopathology
  • Female
  • Gastric Emptying / drug effects*
  • Gastroparesis / diagnosis
  • Gastroparesis / drug therapy*
  • Gastroparesis / microbiology
  • Gastroparesis / physiopathology
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter Infections / physiopathology
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / pathogenicity
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Nausea / drug therapy
  • Nausea / microbiology
  • Nausea / physiopathology
  • Odds Ratio
  • Proton Pump Inhibitors / therapeutic use*
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Dopamine Antagonists
  • Proton Pump Inhibitors